FTRE
Fortrea Holdings Inc.
FTRE offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over FTRE overall, supported by stronger fundamentals and lower modeled downside.
FTRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
FTRE's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FTRE PE Valuation
FTRE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FTRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect FTRE's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over FTRE on the outlook, with more favorable revenue expectations.
FTRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.95 | — |
| Q3 2026 | -$0.63 | +$10.61 |
| Q2 2026 | -$0.81 | +$10.57 |
| Q1 2026 | -$4.81 | +$3.98 |
| Q4 2025 | -$10.81 | -$7.14 |
| Q3 2025 | -$11.24 | -$7.84 |
| Q2 2025 | -$11.38 | -$8.14 |
| Q1 2025 | -$8.79 | -$7.42 |
| Q4 2024 | -$3.67 | -$3.57 |
FTRE is still losing money, but far less than before: $0.63 per share over the past year, against $11.38 at its worst in mid-2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over FTRE on earnings quality, reporting a profit while its opponent remains loss making.
FTRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $691.5M | -1.4% |
| Q2 2026 | $678.2M | -4.5% |
| Q1 2026 | $636.5M | -2.3% |
| Q4 2025 | $660.5M | -5.2% |
| Q3 2025 | $701.3M | +3.9% |
| Q2 2025 | $710.3M | +7.2% |
| Q1 2025 | $651.3M | -1.6% |
| Q4 2024 | $697M | -10% |
FTRE's revenue has held roughly level: $692M last quarter, down 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.2% | +3.4 points |
| Q2 2026 | 2.2% | +49 points |
| Q1 2026 | -0.5% | +79 points |
| Q4 2025 | -2.1% | +5.9 points |
| Q3 2025 | -1.2% | +1.4 points |
| Q2 2025 | -47% | -39 points |
| Q1 2025 | -80% | -74 points |
| Q4 2024 | -8% | -6.6 points |
FTRE's operating margin was 2.2% last quarter, up 3.4 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FTRE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over FTRE on profitability, with a higher operating margin.
FTRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.5M | -34% |
| Q2 2026 | $19.9M | +39% |
| Q1 2026 | -$25M | +$102.1M |
| Q4 2025 | $121.6M | +499% |
| Q3 2025 | $79.5M | +$90.1M |
| Q2 2025 | $14.3M | -95% |
| Q1 2025 | -$127.1M | -$92.2M |
| Q4 2024 | $20.3M | +577% |
FTRE's free cash flow has turned positive again: $169M over the past year, against −$13M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FTRE on cash flow, with more consistent year-over-year improvement.
FTRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.8% | +6.4M shares |
| 1 year | +9.5% | +8.8M shares |
| 3 years | +14% | +12.4M shares |
FTRE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FTRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.1x | High |
| Q2 2026 | 13.1x | High |
| Q2 2024 | 118.8x | High |
| Q1 2024 | 15.7x | High |
| Q4 2023 | 10.0x | High |
| Q3 2023 | 10.6x | High |
| Q2 2023 | 7.5x | High |
| Q1 2023 | 6.2x | High |
FTRE's net debt is about 9.1 years of its operating earnings (EBITDA), down from 10 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over FTRE on leverage, with a lower net debt burden relative to earnings.
FTRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 49.9 | Neutral |
FTRE's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FTRE PE vs Healthcare Sector
FTRE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FTRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.3 | 5.7% below |
| 20 week MA | $19.5 | 3% above |
| 50 week MA | $15.9 | 26% above |
| 100 week MA | $12.9 | 56% above |
OSCR has stronger trend alignment. FTRE is above 3 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
FTRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $34.0 | $34.9 | +2.6% |
| 2024 | $34.9 | $19.4 | -45% |
| 2025 | $19.4 | $17.4 | -10% |
| 2026 YTD | $17.4 | $20.1 | +15% |
FTRE has finished lower in two of the last three years. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FTRE on returns for 2026, with the stronger performance.